AMP Capital Investors Ltd Has $3.59 Million Stake in Alnylam Pharmaceuticals, Inc. (ALNY)

AMP Capital Investors Ltd cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,428 shares of the biopharmaceutical company’s stock after selling 2,300 shares during the quarter. AMP Capital Investors Ltd’s holdings in Alnylam Pharmaceuticals were worth $3,588,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Xact Kapitalforvaltning AB raised its position in shares of Alnylam Pharmaceuticals by 3.1% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 15,929 shares of the biopharmaceutical company’s stock valued at $1,569,000 after buying an additional 486 shares in the last quarter. Guggenheim Capital LLC raised its position in shares of Alnylam Pharmaceuticals by 1.1% in the 1st quarter. Guggenheim Capital LLC now owns 53,084 shares of the biopharmaceutical company’s stock valued at $6,323,000 after buying an additional 600 shares in the last quarter. Toronto Dominion Bank increased its position in Alnylam Pharmaceuticals by 16.1% during the 1st quarter. Toronto Dominion Bank now owns 6,058 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 842 shares in the last quarter. American International Group Inc. increased its position in Alnylam Pharmaceuticals by 44.8% during the 1st quarter. American International Group Inc. now owns 2,906 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 899 shares in the last quarter. Finally, LPL Financial LLC increased its position in Alnylam Pharmaceuticals by 35.6% during the 1st quarter. LPL Financial LLC now owns 3,650 shares of the biopharmaceutical company’s stock worth $435,000 after purchasing an additional 958 shares in the last quarter. Institutional investors own 93.36% of the company’s stock.

Shares of NASDAQ ALNY opened at $93.35 on Tuesday. The company has a quick ratio of 13.22, a current ratio of 13.22 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals, Inc. has a 52-week low of $74.50 and a 52-week high of $153.99. The company has a market capitalization of $9.54 billion, a price-to-earnings ratio of -17.99 and a beta of 2.58.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. The firm had revenue of $29.91 million during the quarter, compared to analysts’ expectations of $16.96 million. During the same period in the prior year, the company posted ($1.07) EPS. The company’s revenue was up 87.8% on a year-over-year basis. research analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.27 earnings per share for the current year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $105.39, for a total value of $5,269,500.00. Following the completion of the transaction, the chief executive officer now directly owns 201,297 shares in the company, valued at approximately $21,214,690.83. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Laurie Keating sold 1,563 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $105.04, for a total transaction of $164,177.52. Following the completion of the transaction, the senior vice president now owns 16,063 shares of the company’s stock, valued at $1,687,257.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,063 shares of company stock valued at $5,733,678. Corporate insiders own 4.30% of the company’s stock.

A number of equities analysts recently issued reports on ALNY shares. Jefferies Financial Group reiterated a “buy” rating and set a $149.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, August 6th. JMP Securities set a $198.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 28th. Piper Jaffray Companies reiterated an “overweight” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 23rd. BidaskClub cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 18th. Finally, Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a “conviction-buy” rating to a “buy” rating in a research report on Monday, August 13th. Three analysts have rated the stock with a sell rating, two have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $145.55.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Read More: How to Use the New Google Finance Tool

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply